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Abstract
Background: Cellular angiofibroma represents a newly described, site specific tumor. Histologically, CAF is a benign
mesenchymal neoplasm characterized by two principal components: bland spindle cells and prominent small to
medium-sized vessels with mural hyalinization. The indolent nature of the lesion is underscored by the uniformity
of its constituent stromal cells, and their lack of nuclear atypia. Characterization by immunohistochemistry is helpful
distinguishing Cellular angiofibroma from other mesenchymal lesions.
Case presentation: We report the case of a 37-year-old woman, presenting with a painless nodule involving the
vulva. This lesion had gradually increased in size; a simple excision was performed, and follow up was
unremarkable. Gross examination showed a well circumscribed, firm tumor measuring 3× 3 × 2,5 cm.
Histologically, the tumor was composed of uniform, short spindle-shaped cells, proliferating in an edematous to
fibrous stroma and numerous small to medium-sized thick-walled vessels. A panel of immunohistochemical stains
was performed, and confirmed the diagnosis of Cellular angiofibroma.
Conclusion: In this report we aim to describe the clinical, pathological and immunohistochemical features of this
rare entity through a literature review, and to discuss other vulvar mesenchymal lesions.
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Background
Cellular angiofibroma (CAF) is a rare benign mesen-
chymal lesion with a predilection for the genitourinary
region. First described in 1997 [1], CAF is characterized
by a spindle cell component and abundant small- to
medium-sized thick-walled vessels [2]. Cases in males
have been previously named “angiomyofibroblastoma-
like tumor”. Besides two small series, cellular angiofi-
broma has been described only in isolated case reports,
we found only 68 patients with genital CAF (Table 1)
[3, 4]. To date, this last condition still remains a poorly
known lesion that needs further investigations to closely
define its clinical and pathological features.
We report a case of cellular angiofibroma, for which
the clinical diagnosis was Bartholin’s glandular cyst.
Case presentation
A healthy 37-year-old woman consulted for an asymp-
tomatic vulvar nodule of 6 years duration. She was
concerned because it had progressively enlarged over
the last few months. There was no history of pain or
bleeding. Local and colposcopic examinations revealed
a 3,5 cm freely mobile non reducible nodule located in
the left labia majora. Ultrasonography showed a super-
ficial, well-demarcated, solid soft tissue tumor. A well
circumscribed lesion measuring 3 cm in diameter was
excised with a rim of normal tissue. Gross examin-
ation showed a well circumscribed, solid, whitish,
glossy tumor measuring 3× 3 × 2,5 cm. Microscopic-
ally, the tumor was well circumscribed, surrounded by
a fibrous pseudocapsule. On low-power examination,
hypocellular and hypercellular areas, composed of uni-
form, short spindle-shaped cells, proliferating in an
edematous to fibrous stroma (Fig. 1). Numerous small
to medium-sized thick-walled vessels were also seen
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Table 1 Summary of the literature review of vulvar CAF reported
Authors Year Age Localisation Treatment Follow-up
Nucci et al. [1] 1997 50 Vulva Complete excision NA
46 Left labia majora Complete excision NR, 19 months
39 Right labia Complete excision NR, 12 months
49 Labia Complete excision NA
Colombat et al. [25] 2001 37 Left labia majora Complete excision NA
Lane et al. [10] 2001 77 Left labia Complete excision NR, 12 months
Curry et al. [18] 2001 37 Clitoral hood NA NR, 15 months
Dufau et al. [16] 2002 53 Labia majora NA NA
Dargent et al. [9] 2003 46 Right labial region NR, 19 months
49 Lateral part of the clitoris. NR, 7 months
McCluggage et al. [22] 2002 49 Left labia majora Complete excision Reccurence 6 months later
Iwasa et al. [3] 2004 49 Labia majora Complete excision NA
39 Vulva NA NA
46 Labia majora Complete excision NR, 16 months
50 Vulva Complete excision Lost
42 Vulva Complete excision NR, 75 months
42 Perineum NA NA
75 Vulva Complete excision Died of breast cancer
41 Vulva Complete excision NR 54 months
68 Vulva Complete excision NR, 17 months
59 Labia majora Complete excision NR, 41 month
49 Vulva NA NA
37 Hymen Local Excision + positive margins NR, 24 months
38 Vagina NA NA
46 Vulva Complete excision NR, 35 months
47 Labium majus Complete excision NR, 44 months
47 Vulva NA NA
48 Labium majus Complete excision NR, 8 months
24 Vagina NA NR, 6 months
58 Vagina Complete excision NA
50 Vulva Complete excision NR, 6 months
58 Vulva Complete excision NR, 9 months
50 Vulva NA NA
W G McCluggage et al. [21] 2004 20 Not specified Complete excision NR, 20 month,
25 Posterior vaginal introitus Complete excision NR, 3 months
65 Left labia minora Complete excision NR, 12 months
41 Left labia majora Complete excision NR, 4 months
59 Right side of vulva Complete excision NR, 18 months
32 Right labia Complete excision NA
Micheletti et al. [8] 2005 51 vulva Complete excision NR, 4 months
Kerkuta et al. [7] 2005 31 small left labial Complete excision NR, 10 month
Chen et al. [11] 2010 58 Vulva Complete excision NR, 75 months
52 Vulva Local Complete excision Dead of carcinoma
34 Vulva Complete excision NA
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(Fig. 2). Mature adipocytes were noted in the periphery in
small clusters. There was no necrosis and few or no mi-
totic figures (Fig. 3). Immunohistochemical staining was
positive for vimentin, CD34 (Fig. 4), focally for actin, and
negative for protein S-100, and desmin. These findings are
consistent with the diagnosis of cellular angiofibroma. At
14 months postoperatively, the patient is doing well with
no signs of recurrence.
Discussion
Tumors primarily arising from the vulvo-vaginal area
are relatively rare and they include soft tissue specific
and non-specific tumors, as well as a spectrum of fibro-
epithelial tumors [5, 6]. Cellular angiofibroma is an
uncommon benign mesenchymal neoplasm, originally
described in the genital region, and occurs equally in
both genders [4]. A marked predilection for the vulva is
observed [2], our review of the literature yielded 68 cases
reported, involving the female genital tract (Table 1).
Women are affected most often in the fifth decade,
whereas males are mainly in the seventh decade [3].
Clinically, cellular angiofibroma is often mistaken for a
Bartholin gland, labial, or submucosal cyst [7].
Etiopathologically, some authors suggested that these
lesions are stem cell–derived, with a capacity for adipose
and myofibroblastic differentiation in accordance with
Table 1 Summary of the literature review of vulvar CAF reported (Continued)
32 Vulva Complete excision NA
25 Vulva Complete excision NR, 42 months
43 Vulva Complete excision NR, 2 months
59 Vulva Complete excision NR, 14 months
46 Vulva Complete excision NR, 4 months
71 Vulva Complete excision NA
39 Vulva Complete excision NR, 7 months
46 Vulva Complete excision NA
Flucke et al. [4] 2011 41 Perineal Complete excision NA
39 Vaginal introitus Excision + positive margins NR, 75 months
50 Vulva Excision + positive margins NR, 55 months
51 Labium majus Marginal excision NR, 66 months
44 Labium majus Complete excision NA
50 Vulva Excision + positive margins NA
48 Vulva Complete excision NA
42 Vulva Complete excision NA
63 Clitoris Excision + positive margins NR, 38 months
27 Labium majus Marginal excision NA
42 Vulva Complete excision NR, 30 month
46 Labium majus Marginal excision NA
55 Vulva Complete excision NR, 12 months
57 Vulva NA NR, 6 months
47 Vulva Excision + positive margins NA
39 Vaginal fornix Marginal excision NA
Present case 2015 37 Left labia majora Complete excision NR, 20 month
NR No Recurrence
NA information not available
Fig. 1 low-power view showing uniform, short spindle-shaped cells
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the influence of hormones, microenvironments, cyto-
kines and growth factors [8].
Histologically, CAF is typically well circumscribed,
composed of two principal components: bland spindle
cells and prominent small to medium-sized vessels with
mural hyalinization [3]. The spindle cells are arranged in
short intersecting fascicles lying between short bundles
of wispy collagen [9]. Hypocellular areas can be seen,
often associated with stromal edema or hyalinization.
Typically, significant pleomorphism and abnormal mi-
toses were absent [3]. The accompanying blood vessels
tend to be thick-walled and even hyalinized [10]. Ma-
ture individual or small clusters of adipocytes can be
present, most often located in the periphery of the le-
sion [2, 3]. Fletcher et al. recently have reported a study
of 13 cases of cellular angiofibroma with atypia and sar-
comatous transformation [11]. The sarcomatous com-
ponent can show variable features (atypical lipomatous
tumor, pleomorphic liposarcoma, and pleomorphic
sarcoma). This phenomenon seems not to predispose
to recurrence based on limited clinical follow-up avail-
able [2, 11].
Immunohistochemically, the tumor cells consistently
are vimentin positive [9]. The expression of CD34 is
seen in 60 % [3]. Characteristically, they do not express
S-100 protein, actin, desmin, or EMA, although a
discrete staining for the last three markers has been re-
ported [3, 9]. Lastly, the tumor cells have been found to
be estrogen (ER) and progesterone receptor (PR) posi-
tive. However, the significance of the positive estrogen
and progesterone receptors in CAF is unknown [7]. In
fact, a subset of mesenchymal cells of the distal female
genital tract normally expresses estrogen and progester-
one receptor and, the neoplastic cells arising from the
vulva, may also show immunoreactivity for ER and/or PR
[12]. Thus, ER or PR immunoreactivity cannot be used to
distinguish CAF and its histological mimics [13]
No specific chromosomal abnormality is found in
CAF, although cytogenetic analysis revealed, in a few
reported cases, the loss of RB1 and FOXO1A1 genes
due to the deletion of the 13q14 region [14]. This typ-
ical loss of genetic material is also shared by myofibro-
blastoma [15].
CAF, myofibroblastoma and angiomyofibroblastoma
are usually considered as specific soft tissue tumors of
the vulvo-vaginal area [16]. These tumors may show
overlapping morphological, immunohistochemical and
cytogenetic features, and thus differential diagnosis is
mandatory [17, 15].
Clinically, the age of onset of CAF occurs approxi-
mately 10 years later in life than aggressive angiomyx-
oma, myofibroblastoma and angiomyofibroblastoma
[18]. Histologically, aggressive angiomyxoma is poorly
circumscribed, typically infiltrates adjacent soft tissue,
and characterized by being composed of relatively uni-
form spindle cells, embedded in a myxoid matrix [10].
Fig. 3 Bland spindle cells with uniform nuclei and pale
indistinct cytoplasm
Fig. 4 tumour cells exhibiting diffuse positivity with CD34Fig. 2 Numerous small to medium-sized with thick and hyalinized walls
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AMF is a benign tumor which belongs to the category
of the “stromal tumors of the lower female genital
tract”, together with cellular angiofibroma and myofi-
broblastoma [19]. It is characterized by the presence of
multinucleate cells and epithelioid or plasmacytoid
cells which tend to aggregate around blood vessels
which are thin-walled [21]. However recent cytogenetic
analyses have shown that only CAF and myofibroblas-
toma are genetically related lesions because angiomyo-
fibroblastoma lacks 13q14 deletion [20].
Myofibroblastoma is composed of ovoid- to spindle-
or stellate-shaped cells, arranged in a variety of archi-
tectural patterns and set in a finely collagenous stroma.
Hyalinized blood vessels are a diagnostic clue helpful in
distinguishing cellular angiofibroma from myofibroblas-
toma [15].
Based on morphological, immunohistochemical and
cytogenetic analyses, it has been postulated that CAF
and myofibroblastoma of the lower female genital tract
are closely related lesions that form a continuous
spectrum of a single entity with different morphologic
presentations, likely arising from a common precursor
mesenchymal cell [19].
Desmin seems to be a discriminating marker, as ag-
gressive angiomyxoma, myofibroblastoma and angio-
myofibroblastoma are positive for this antibody [3, 15].
Other neoplasms that are not specific to the vulva,
such as solitary fibrous tumour, spindle cell lipoma,
smooth muscle tumours, nerve sheath tumours, and
perineurioma, also enter into the differential diagnosis
[22].
Spindle cell lipoma is composed of brightly, eosino-
philic ropy and refractile stromal collagen bands with
fewer capillary-sized thin-walled vessels, compared with
palely eosinophilic and wispy collagen fibers associated
with numerous thick-walled vessels in CAF [3, 18]. Soli-
tary fibrous tumor (SFT) can be differentiated by the
presence of thin-walled branching vascular pattern that
may be described as hemangiopericytoma-like vessels,
and dense collagen bundles [12, 23]. SFT shows positiv-
ity for CD34, CD99, bcl-2, and ER and/or PR, and nega-
tivity for SMA and desmin [24].
Other mesenchymal lesions (schwannoma, perineur-
ioma and leiomyoma) can be ruled out in accordance
with the histology and immunohistochemistry [8].
CAF behaves in a benign fashion and local excision
with clear margins is the treatment of choice. This lesion
shows no tendency for metastasis based on the limited
clinical follow-up available [2, 3, 7]. However, there is
one case of recurrent CAF, reported by McCluggage et
al., in which a 49-year-old woman had recurrent swelling
develop at the site of the previous excision 6 months
later [22]. Our patient is well without evidence of local
recurrence 20 months after excision.
Conclusions
CAF represents a rare distinct clinico-pathological condi-
tion, that pathologists should be aware of morphological
variation (Atypia and Sarcomatous transformation) to pre-
vent diagnostic errors and therefore an aggressive therapy.
As far as we are aware, no case of metastatic CAF has
been described.
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